StockData
Elicio Therapeutics, Inc. logo

Elicio Therapeutics, Inc. (ELTX) stock

ELTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 1/30
$1.43−0.05 (-3.38%)

Close on Nov 17, 2026Market cap $37.58MP/E –Yield –

Elicio Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Elicio Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$37.69M. For fiscal 2025 it was -$36.95M. The highest annual figure on record is -$22.18M in fiscal 2022.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$36.95M–
FY2024Dec 31, 2024-$37.07M–
FY2023Dec 31, 2023-$32.69M–
FY2022Dec 31, 2022-$22.18M–
FY2021Dec 31, 2021-$52.64M–
FY2020Dec 31, 2020-$22.89M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$8.17M–
Q1 FY2026Mar 31, 2026-$11.65M–
Q4 FY2025Dec 31, 2025-$6.80M–
Q3 FY2025Sep 30, 2025-$11.09M–
Q2 FY2025Jun 30, 2025-$8.95M–
Q1 FY2025Mar 31, 2025-$10.12M–
Q4 FY2024Dec 31, 2024-$8.74M–
Q3 FY2024Sep 30, 2024-$7.27M–
Q2 FY2024Jun 30, 2024-$8.93M–
Q1 FY2024Mar 31, 2024-$12.12M–
Q4 FY2023Dec 31, 2023-$9.90M–
Q3 FY2023Sep 30, 2023-$5.19M–
Q2 FY2023Jun 30, 2023-$9.48M-254.4%
Q1 FY2023Mar 31, 2023-$8.14M–
Q4 FY2022Dec 31, 2022-$7.28M–
Q3 FY2022Sep 30, 2022-$5.39M–
Q2 FY2022Jun 30, 2022$6.14M–
Q1 FY2022Mar 31, 2022-$15.65M–
Q4 FY2021Dec 31, 2021-$14.36M-169.7%
Q3 FY2021Sep 30, 2021-$15.20M–
Q2 FY2021Jun 30, 2021-$10.53M–
Q1 FY2021Mar 31, 2021-$12.55M–
Q4 FY2020Dec 31, 2020$20.59M–
Q3 FY2020Sep 30, 2020-$21.94M–
Q2 FY2020Jun 30, 2020-$12.80M–
Q1 FY2020Mar 31, 2020-$8.73M–

More Elicio Therapeutics figures

See a number that looks wrong?